Results Mixed on Merck's New Painkiller
13th Nov 2006, 14:23 GMT
CHICAGO (AP) - The first published studies of Arcoxia, the drug that Merck & Co. hopes will take the place of its withdrawn painkiller Vioxx, are getting mixed reviews from doctors, some of whom say the results do not make a case for the medication's approval.
Results Mixed on Merck's New Painkiller related news:
- Docs Give Merck Painkiller Acroxia Mixed Reviews — FOXNews.com
- Results Mixed on Merck's New Painkiller — AP Top Health News At 9 a.m.
- Results mixed on Merck's new painkiller (AP) — Yahoo! News: Health News
- Results mixed on Merck's new painkiller (Associated Press) — Yahoo! Health: Health News
- Results on Merck's new painkiller draw mixed reviews — azcentral.com | business
- Tests of new Merck painkiller criticized — baltimoresun.com - health & science
- Merck: New pain killer safer than Vioxx — Business and financial news - CNNMoney.com
- Merck says new drug is safer than Vioxx — Cardiology News from StratCenter.com
- Mixed reviews for Vioxx successor — MSNBC.com: Health
- Vioxx-Like Drug Gets Mixed Reviews — Dayton Daily News National Headlines
Latest news from LancasterOnline - Health:
- Group Gives Advice on Face Transplants
- Hospitals Want Faster Heart Attack Care
- Restaurant Assoc. Sues Over Health Care
- Red Meat May Raise Breast Cancer Risk
- Health Care Costs Could Jump 10 Percent
- Tamiflu May Get 'Abnormal Behavior' Label
- More South Africans Get AIDS Medicine
- Japan Confirms 30th Mad Cow Case
- Bush to Host Summit on Malaria
- FDA: Tamiflu Patients Need Monitoring